Wall Street analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce $720,000.00 in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $350,000.00 and the highest estimate coming in at $1.75 million. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.89 million for the current financial year, with estimates ranging from $750,000.00 to $4.25 million. For the next fiscal year, analysts anticipate that the company will post sales of $2.62 million, with estimates ranging from $600,000.00 to $7.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million.

SYRS has been the subject of several research analyst reports. BidaskClub downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research note on Tuesday, July 17th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Cann reissued a “buy” rating and issued a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.29.

A number of large investors have recently modified their holdings of SYRS. BlackRock Inc. raised its stake in Syros Pharmaceuticals by 70.4% in the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock worth $16,169,000 after buying an additional 654,094 shares in the last quarter. ARK Investment Management LLC raised its stake in Syros Pharmaceuticals by 19.6% in the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock worth $18,373,000 after buying an additional 294,663 shares in the last quarter. Millennium Management LLC raised its stake in Syros Pharmaceuticals by 129.3% in the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after buying an additional 211,696 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals in the second quarter worth approximately $1,703,000. Finally, Renaissance Technologies LLC purchased a new position in Syros Pharmaceuticals in the second quarter worth $1,684,000. 60.70% of the stock is owned by institutional investors.

Shares of Syros Pharmaceuticals stock traded down $0.63 on Monday, hitting $6.79. 10,268 shares of the company traded hands, compared to its average volume of 186,292. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $17.50. The company has a market capitalization of $400.82 million, a PE ratio of -3.39 and a beta of -1.96.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Read More: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.